Canaccord Genuity analyst Matt Bottomley maintained a Buy rating on Columbia Care (OTC:CCHWF) on Friday, setting a price target of C$13, which is approximately 151.27% above the present share price of $3.95.
Bottomley expects Columbia Care to post earnings per share (EPS) of -$0.11 for the fourth quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Columbia Care, with an average price target of $7.5.
The analysts price targets range from a high of $9.91 to a low of $5.34.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $28.41 million and a net profit of -$42.98 million. The company's market cap is $1.02 billion.
According to TipRanks.com, Canaccord Genuity analyst Matt Bottomley is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.7% and a 50.87% success rate.
Columbia Care, Inc. engages in the cultivation, manufacture and provision of medical cannabis products and services. It distributes its products under the EleCeed, TheraCeed, and ClaraCeed brands. The company was founded by Nicholas Vita and Michael Abbott in 2012 and is headquartered in New York, NY.